Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.HIV guidelines support use of Roche drug
This duel treatment approach is thought to result in better and more prolonged virologic suppression. The guidelines are designed to provide clinicians and other healthcare providers with directions
This duel treatment approach is thought to result in better and more prolonged virologic suppression. The guidelines are designed to provide clinicians and other healthcare providers with directions
The trial is a post-market registry, prospective, multi-center study taking place in Europe, Asia and other areas outside of the US. This registry is designed to evaluate real-world
The novel, fully human, antagonist antibody targets the CD40 antigen which is associated with multiple myeloma. The single-agent, open-label phase I study of CHIR-12.12 will recruit up to
The collaboration calls for the use of the Aqua platform to generate in situ proteomic information to elucidate different aspects of Lilly’s drug discovery and development pathway. Terms
The Committee for Orphan Medical Products, a division of the European Medicines Agency (EMEA), recommended the designation for Tilarginine Acetate Injection (TAI) for the treatment of cardiogenic shock.
The companies believe their diagnostic tests to be completely novel. They believe the tests could enable the detection of cancer from a simple blood sample and at a
This designation indicates that the appropriate information has been provided for the review of the new drug application. The company believes that this review will be completed within
The company has also entered a cooperative R&D agreement with the National Cancer Institute, a collaborator in the development of the RTA 401 compound. RTA 401 is the
The safety and efficacy study will evaluate Merrimack’s lead product MM-093, a recombinant version of human alpha-fetoprotein (AFP). The placebo controlled study will enroll approximately 30 adult outpatients
Benign prostatic hyperplasia afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with